Perioperative transfusion of leukocyte depleted blood products in gastric cancer patients negatively influences oncologic outcome: A retrospective propensity score weighted analysis on 610 curatively resected gastric cancer patients

Medicine (United States)

Volumn 95, Issue 29, 2016, Pages

  Reim, Daniel ^a   Strobl, Andreas N ^a   Buchner, Christian ^a   Schirren, Rebekka ^a   Mueller, Werner ^b   Luppa, Peter ^b   Ankerst, Donna Pauler ^a   Friess, Helmut ^a   Novotny, Alexander ^a  

^a TECHNICAL UNIVERSITY OF MUNICH   (Germany)

^b TECHNICAL UNIVERSITY OF MUNICH   (Germany)

Author keywords

Gastric cancer; Perioperative blood transfusion; Prognosis

Indexed keywords

ANTINEOPLASTIC AGENT;

ADULT; AGE; AGED; BLOOD; BLOOD TRANSFUSION; CANCER ADJUVANT THERAPY; CANCER LOCALIZATION; CANCER MORTALITY; CANCER PATIENT; CANCER PROGNOSIS; CANCER RISK; CANCER STAGING; CANCER SURGERY; CANCER SURVIVAL; CONTROLLED STUDY; FEMALE; GASTRECTOMY; HUMAN; LEUKOCYTE DEPLETED BLOOD PRODUCT; LYMPH NODE METASTASIS; MAJOR CLINICAL STUDY; MALE; MORTALITY RATE; OUTCOME ASSESSMENT; OVERALL SURVIVAL; PERIOPERATIVE PERIOD; POSTOPERATIVE COMPLICATION; POSTOPERATIVE PERIOD; PRIORITY JOURNAL; PROPENSITY SCORE; RECURRENCE FREE SURVIVAL; RECURRENCE RISK; RETROSPECTIVE STUDY; REVIEW; STOMACH CANCER; SURVIVAL RATE; TERTIARY HEALTH CARE; ADJUVANT CHEMOTHERAPY; KAPLAN MEIER METHOD; LEUKAPHERESIS; MIDDLE AGED; MORTALITY; NEOADJUVANT THERAPY; PROPORTIONAL HAZARDS MODEL; RISK FACTOR; STOMACH NEOPLASMS; TUMOR RECURRENCE;

AGED; BLOOD TRANSFUSION; CHEMOTHERAPY, ADJUVANT; FEMALE; HUMANS; KAPLAN-MEIER ESTIMATE; LEUKOCYTE REDUCTION PROCEDURES; MALE; MIDDLE AGED; NEOADJUVANT THERAPY; NEOPLASM RECURRENCE, LOCAL; PERIOPERATIVE CARE; POSTOPERATIVE COMPLICATIONS; PROPENSITY SCORE; PROPORTIONAL HAZARDS MODELS; RETROSPECTIVE STUDIES; RISK FACTORS; STOMACH NEOPLASMS;

EID: 84979994112     PISSN: 00257974     EISSN: 15365964     Source Type: Journal    
DOI: 10.1097/MD.0000000000004322     Document Type: Review

References (32)

1. Guggenheim DE, Shah M.A. Gastric cancer epidemiology and risk factors. J Surg Oncol 2013;107:230-6.
2. Lagarde SM, ten Kate FW, Reitsma JB, et al. Prognostic factors in adenocarcinoma of the esophagus or gastroesophageal junction. J Clin Oncol 2006;24:4347-55.
3. Cunningham D, Allum WH, Stenning SP, et al. Perioperative chemotherapy versus surgery alone for resectable gastroesophageal cancer. N Engl J Med 2006;355:11-20.
4. Ychou M, Boige V, Pignon J-P, et al. Perioperative chemotherapy compared with surgery alone for resectable gastroesophageal adenocar-cinoma: an FNCLCC and FFCD multicenter phase III Trial. J Clin Oncol 2011;29:1715-21.
5. van Hagen P, Hulshof MC, van Lanschot JJ, et al. Preoperative chemoradiotherapy for esophageal or junctional cancer. N Engl J Med 2012;366:2074-84.
6. Songun I, Putter H, Kranenbarg EM-K, et al. Surgical treatment of gastric cancer: 15-year follow-up results of the randomised nationwide Dutch D1D2 trial. Lancet Oncol 2010;11:439-49.
7. Kutup A, Nentwich MF, Bollschweiler E, et al. What should be the gold standard for the surgical component in the treatment of locally advanced esophageal cancer: transthoracic versus transhiatal esophagectomy. Ann Surg 2014;260:1016-22.
8. Sun C, Wang Y, Yao HS, et al. Allogeneic blood transfusion and the prognosis of gastric cancer patients: systematic review and meta-analysis. Int J Surg 2015;13:102-10.
9. Austin PC. The use of propensity score methods with survival or time-to-event outcomes: reporting measures of effect similar to those used in randomized experiments. Stat Med 2014;33:1242-58.
10. Bundesärztekammer. Guidelines for the extraction of blood and blood components and the use of blood products (hemotherapy) 16.04.2010. Available at: http://www.bundesaerztekammer.de/fileadmin/user-up load/downloads/RiliHaemotherapie2010.pdf. Accessed 20.01.2016.
11. Xie J, Liu C. Adjusted Kaplan-Meier estimator and log-rank test with inverse probability of treatment weighting for survival data. Stat Med 2005;24:3089-110.
12. Blumberg N, Heal JM, Murphy P, et al. Association between transfusion of whole blood and recurrence of cancer. Br Med J (Clin Res Ed) 1986;293:530-3.
13. Moriguchi S, Maehara Y, Akazawa K, et al. Lack of relationship between perioperative blood transfusion and survival time after curative resection for gastric cancer. Cancer 1990;66:2331-5.
14. Fong Y, Karpeh M, Mayer K, et al. Association of perioperative transfusions with poor outcome in resection of gastric adenocarcinoma. Am J Surg 1994;167:256-60.
15. Choi JH, Chung HC, Yoo NC, et al. Perioperative blood transfusions and prognosis in patients with curatively resected locally advanced gastric cancer. Oncology 1995;52:170-5.
16. Sanchez-Bueno F, Garcia-Marcilla JA, Perez-Abad JM, et al. Does perioperative blood transfusion influence long-term prognosis of gastric cancer? Dig Dis Sci 1997;42:2072-6.
17. Heiss MM, Allgayer H, Gruetzner KU, et al. Prognostic influence of blood transfusion on minimal residual disease in resected gastric cancer patients. Anticancer Res 1997;17:2657-61.
18. Dhar DK, Kubota H, Tachibana M, et al. A tailored perioperative blood transfusion might avoid undue recurrences in gastric carcinoma patients. Dig Dis Sci 2000;45:1737-42.
19. Hyung WJ, Noh SH, Shin DW, et al. Adverse effects of perioperative transfusion on patients with stage III and IV gastric cancer. Ann Surg Oncol 2002;9:5-12.
20. Ojima T, Iwahashi M, Nakamori M, et al. Association of allogeneic blood transfusions and long-term survival of patients with gastric cancer after curative gastrectomy. J Gastrointest Surg 2009;13:1821-30.
21. Lin SJ, Gagnon-Bartsch JA, Tan IB, et al. Signatures of tumour immunity distinguish Asian and non-Asian gastric adenocarcinomas. Gut 2015;64:1721-31.
22. Weitz J, D'Angelica M, Gonen M, et al. Interaction of splenectomy and perioperative blood transfusions on prognosis of patients with proximal gastric and gastroesophageal junction cancer. J Clin Oncol 2003;21:4597-603.
23. Pacelli F, Rosa F, Marrelli D, et al. Do perioperative blood transfusions influence prognosis of gastric cancer patients? Analysis of 927 patients and interactions with splenectomy. Ann Surg Oncol 2011;18:1615-23.
24. Rausei S, Ruspi L, Galli F, et al. Peri-operative blood transfusion in gastric cancer surgery: prognostic or confounding factor? Int J Surg 2013;11(suppl 1):S100-3.
25. Muller MM, Geisen C, Zacharowski K, et al. Transfusion of packed red cells. Dtsch Arztebl Int 2015;112:507-18.
26. Carson JL, Carless PA, Hebert PC. Transfusion thresholds and other strategies for guiding allogeneic red blood cell transfusion. Cochrane Database Syst Rev 2012;4: CD002042.
27. Reim D, Loos M, Vogl F, et al. Prognostic implications of the seventh edition of the international union against cancer classification for patients with gastric cancer: the Western experience of patients treated in a single-center European institution. J Clin Oncol 2013;31:263-71.
28. Rosenbaum PR, Rubin DB. The central role of the propensity score in observational studies for causal effects. Biometrika 1983;70:41-55.
29. Kuss O, Legler T, Borgermann J. Treatments effects from randomized trials and propensity score analyses were similar in similar populations in an example from cardiac surgery. J Clin Epidemiol 2011;64:1076-84.
30. Lonjon G, Boutron I, Trinquart L, et al. Comparison of treatment effect estimates from prospective nonrandomized studies with propensity score analysis and randomized controlled trials of surgical procedures. Ann Surg 2014;259:18-25.
31. Austin PC, Schuster T. The performance of different propensity score methods for estimating absolute effects of treatments on survival outcomes: a simulation study. Stat Methods Med Res 2014;0:1-24.
32. Shander A, Van Aken H, Colomina MJ, et al. Patient blood management in Europe. Br J Anaesth 2012;109:55-68.